SGLT2 HYPE
A project for improving hypertension treatment
Hypertension, a leading cause of serious heart and kidney diseases, affects over 80 million people in the EU and contributes to one million deaths annually. Despite the availability of treatments, many patients continue to face significant health risks due to inadequate blood pressure control.
SGLT2 inhibitors, a class of drugs commonly used for diabetes and heart failure, have shown potential in lowering blood pressure and providing organ protection due to pleiotropic effects. However, research is required to confirm their effectiveness in hypertension management. SGLT2 HYPE aims to address this evidence gap to improve the prognosis of millions of patients with hypertension.

News & Events
New EU-funded Project Aims to Transform Hypertension Treatment
SGLT2 HYPE is a guideline-relevant clinical trial aiming to establish SGLT2 inhibitors as a new standard in high blood pressure therapy, ultimately addressing one of the leading causes of premature mortality in Europe